ARP Global Capital Ltd Acquires New Position in Eli Lilly and Company $LLY

ARP Global Capital Ltd bought a new position in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, Holdings Channel reports. The institutional investor bought 15,840 shares of the company’s stock, valued at approximately $17,023,000. Eli Lilly and Company makes up about 5.1% of ARP Global Capital Ltd’s holdings, making the stock its 6th biggest position.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Farmers National Bank grew its position in Eli Lilly and Company by 8.4% during the fourth quarter. Farmers National Bank now owns 4,456 shares of the company’s stock valued at $4,789,000 after acquiring an additional 345 shares during the last quarter. Winthrop Partners WNY LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $644,000. Nalls Sherbakoff Group LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $46,000. Meadowbrook Advisors Group LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $764,000. Finally, Green Ridge Wealth Planning LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $925,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LLY. Leerink Partners boosted their price target on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a research note on Thursday, February 5th. Daiwa Securities Group raised their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Wolfe Research raised their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,229.59.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $977.47 on Friday. The business has a 50 day moving average of $1,039.17 and a 200 day moving average of $947.29. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a market cap of $923.54 billion, a PE ratio of 42.59, a P/E/G ratio of 1.16 and a beta of 0.40. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the previous year, the business posted $5.32 earnings per share. The firm’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Medicare access is expanding for Zepbound and Mounjaro, which should boost near‑term demand and reduce payer uncertainty for a large patient cohort. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Lilly announced a multibillion manufacturing build‑out in China to secure supply and capture a huge GLP‑1 market — a strategic long‑term revenue driver. Lilly to Invest $3 Billion in China to Boost Obesity Pill
• Positive Sentiment: Lilly is expanding manufacturing and partnerships in Asia (Korea $500M incubator and Japan plant expansion), diversifying capacity and helping global rollout. Eli Lilly invests $500 million in Korea’s biotech growth
• Positive Sentiment: Lilly is pushing multiple product catalysts: an orforglipron filing/launch (oral GLP‑1) and follow‑on candidates (retatrutide) that can sustain growth beyond current injectables. Will Policy Shifts Accelerate Demand for Eli Lilly’s GLP‑1 Drugs?
• Positive Sentiment: Employer Connect and LillyDirect initiatives aim to expand coverage and patient access (potential volume growth even if pricing is pressured). Lilly Employer Connect platform launch
• Neutral Sentiment: Premium share price and 5‑year outperformance have reignited stock‑split and megatrend commentary — sentiment boosters but not immediate fundamentals. Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years (LLY)
• Negative Sentiment: Lilly issued warnings after detecting an unknown impurity in compounded tirzepatide mixed with vitamin B12 — a safety/regulatory concern that can drive near‑term caution and compounding‑market scrutiny. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Shorter‑term technical/market‑sentiment concerns: some analysts/public pieces argue trading momentum has cooled since late 2025, which can accelerate sell‑offs after recent gains. Eli Lilly Reaching For Peak GLP‑1 Euphoria: Rotten Trading Momentum Since November
• Negative Sentiment: Lilly warned some Medicare plans or basic Part D designs might still leave patients with >$50 out‑of‑pocket costs under new CMS rules — a potential near‑term headwind to access and PR. Lilly Warns Some Medicare GLP‑1 Costs Could Exceed $50

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.